期刊
ARCHIVES OF GENERAL PSYCHIATRY
卷 69, 期 10, 页码 1054-1063出版社
AMER MEDICAL ASSOC
DOI: 10.1001/archgenpsychiatry.2011.2188
关键词
-
类别
资金
- Actelion
- Affectis
- Astra-Zeneca
- Brain-Lab
- Daimler Benz
- Essex
- GlaxoSmithKline
- Lundbeck
- Neurim
- NeuroBiotec
- Neurocrine
- Novartis
- Organon
- Sanofi
- Schwarz
- Sepracor
- Takeda
- UCB
- Volkswagen
- Weinmann
- Wyeth
- Aventis
- Cephalon
- Pfizer
- SchoeringPlough
- Somaxon
- Somnus
- Syrex
- TransOral
- Ventus
- Xenoport
- Merck Co.
- Merck Co
Context: Insomnia is a common and seriously impairing condition that often goes unrecognized. Objectives: To examine associations of broadly defined insomnia (ie, meeting inclusion criteria for a diagnosis from International Statistical Classification of Diseases, 10th Revision, DSM-IV, or Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition) with costly workplace accidents and errors after excluding other chronic conditions among workers in the America Insomnia Survey (AIS). Design/Setting: A national cross-sectional telephone survey (65.0% cooperation rate) of commercially insured health plan members selected from the more than 34 million in the HealthCore Integrated Research Database. Participants: Four thousand nine hundred ninetyone employed AIS respondents. Main Outcome Measures: Costly workplace accidents or errors in the 12 months before the AIS interview were assessed with one question about workplace accidents that either caused damage or work disruption with a value of $500 or more and another about other mistakes that cost your company $500 or more. Results: Current insomnia with duration of at least 12 months was assessed with the Brief Insomnia Questionnaire, a validated (area under the receiver operating characteristic curve, 0.86 compared with diagnoses based on blinded clinical reappraisal interviews), fully structured diagnostic interview. Eighteen other chronic conditions were assessed with medical/pharmacy claims records and validated self-report scales. Insomnia had a significant odds ratio with workplace accidents and/or errors controlled for other chronic conditions (1.4). The odds ratio did not vary significantly with respondent age, sex, educational level, or comorbidity. The average costs of insomnia-related accidents and errors ($32062) were significantly higher than those of other accidents and errors ($21914). Simulations estimated that insomnia was associated with 7.2% of all costly workplace accidents and errors and 23.7% of all the costs of these incidents. These proportions are higher than for any other chronic condition, with annualized US population projections of 274 000 costly insomnia-related workplace accidents and errors having a combined value of US $31.1 billion. Conclusion: Effectiveness trials are needed to determine whether expanded screening, outreach, and treatment of workers with insomnia would yield a positive return on investment for employers. Arch Gen Psychiatry. 2012;69(10):1054-1063
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据